Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine
Hyemin Chung,
Jongsung Lee,
Kyungrok Minn,
Jiyoung Lee,
Soyoung Yun,
Joung Ha Park,
Min-Chul Kim,
Seong-Ho Choi,
Jin-Won Chung
Affiliations
Hyemin Chung
Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul 06973, Republic of Korea
Jongsung Lee
College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea
Kyungrok Minn
College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea
Jiyoung Lee
College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea
Soyoung Yun
College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea
Joung Ha Park
Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong 14353, Republic of Korea
Min-Chul Kim
Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong 14353, Republic of Korea
Seong-Ho Choi
Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul 06973, Republic of Korea
Jin-Won Chung
Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul 06973, Republic of Korea
We evaluated the immune response against the Omicron variant after mRNA-based COVID-19 booster vaccination in medical students. We prospectively enrolled medical students who received two primary doses of the mRNA-1273 vaccine. The neutralizing response and the SARS-CoV-2-specific T-cell response was evaluated. A total of 56 serum samples were obtained before booster vaccination. Nineteen students (33.9%) developed COVID-19 two months after booster vaccination. Of 56 students, 35 students (12 infected and 23 uninfected) were available for blood sampling four months after booster vaccination. In comparison with uninfected students, infected students showed a significantly higher level of SARS-CoV-2-specific IgG (5.23 AU/mL vs. 5.12 AU/mL, p p p = 0.02). In our study, booster vaccination with mRNA-1273 instead of BNT162b2 was significantly associated with a higher neutralizing response.